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E. Murat Tuzcu, MD, Samir R. Kapadia, MD, Lars G. Svensson, MD, PHDSEE PAGE 2184O n April 16, 2002, Alain Cribier, MD, raisedthe ﬂag of innovation in the treatment ofvalvular heart disease. He performed a
transcatheter aortic valve replacement (TAVR) in a
desperately-ill patient who was days from death.
The patient survived the procedure and died
4 months later from noncardiac causes. Following
other successful cases, the subsequent decade was
ﬁlled with incredible advances in technology, pa-
tient selection, operator technique, systematic
data collection and analysis. New iterations of the
balloon-expandable and self-expanding transcatheter
valves allow operators to consistently and safely
achieve successful results. The ﬁrst reported random-
ized PARTNER (Placement of Aortic Transcatheter
Valves) trial demonstrated TAVR’s lifesaving value
in patients with symptomatic aortic stenosis (AS)
who were unsuitable candidates for surgical treat-
ment (1). Recently, the 5-year follow-up of this study
demonstrated this intervention’s durability (2). This
and subsequent randomized trials were conducted
rigorously, in a true partnership of all stakeholders,
setting a new standard in valvular heart disease treat-
ment (Figure 1).
Shortly after the initial reported success of TAVR in
inoperable patients, attention turned toward oper-
able but high-risk patients. The PARTNER 1A Trial
demonstrated noninferiority of TAVR to surgical
aortic valve replacement (SAVR) with the ﬁrst-
generation balloon-expandable valve (3). Another
randomized study demonstrated that TAVR with a
self-expanding valve was superior to SAVR at 1 year in
high-risk patients whose mean predicted 30-day
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using this new technique in lower-risk patients. Two
randomized trials, designed to answer the question
of safety and efﬁcacy of TAVR in intermediate-risk
patients, began enrollment a few years ago. PART-
NER 2A, in which patients were randomized to TAVR
utilizing a balloon-expandable valve or SAVR, com-
pleted enrollment in 2014 with results expected in
2016. The SURTAVI (Surgical Replacement and Trans-
catheter Aortic Valve Implantation [NCT01586910])
trial, which has a similar design using a self-expanding
valve, is continuing enrollment.
Increasing experience and technological advances
have led to even better outcomes and continued
reassessment of TAVR’s role in treating symptomatic
severe AS. Characterization of risk has changed over
time. The Society of Thoracic Surgeons (STS) score of
contemporary “high-risk” patients is much lower
than the mean score of 11.8% in PARTNER A; the
mean predicted surgical mortality risk (STS score) in
the TVT (Transcatheter Valve Therapies) registry,
which includes high-risk or inoperable U.S. pa-
tients, is 7.1% (5). As practice changed, investigators
evaluated TAVR outcomes in intermediate- and
even low-risk patients. In various nonrandomized
propensity-matched analyses, TAVR was as efﬁca-
cious and safe as SAVR in lower-risk patients (6).In this issue of the Journal, Thyregod et al. (7)
aimed to determine whether TAVR and SAVR out-
comes are similar in an all-comers population over the
age of 70 years. The Danish and Swedish investigators
should be congratulated for conducting the ﬁrst ran-
domized trial in lower-risk AS patients. The NOTION
(Nordic Aortic Valve Intervention) trial, funded by
the Danish Heart Foundation, retained 96% of pa-
tients at 1-year follow-up and used Valve Academic
Research Consortium-2 deﬁnitions for endpoints.
The combined primary endpoint was all-cause
mortality, stroke, and myocardial infarction at
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In these results of randomized trials with transcatheter aortic valve replacement (TAVR) in different groups of patients with symptomatic aortic
stenosis, the vertical bar represents different patient risk levels. Device comparison trials are not included. It is evident that as TAVR is
performed in lower-risk patients, TAVR outcomes are improving. Although the NOTION (Nordic Aortic Valve Intervention) trial provides some
data in a lower-risk group, the lack of equivalence of outcomes for TAVR and surgical aortic valve replacement (SAVR) point to the need for
more data. AR ¼ aortic regurgitation; PARTNER ¼ Placement of Aortic Transcatheter Valves; ST ¼ standard treatment; STS ¼ Society of
Thoracic Surgeons; SURTAVI ¼ Surgical Replacement and Transcatheter Aortic Valve Implantation.
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21961 year, which was similar in both groups. Individually,
all-cause mortality, stroke, myocardial infarction,
and new-onset or worsening atrial ﬁbrillation rates
were not signiﬁcantly different but were numeri-
cally lower in TAVR patients. Major life-threatening
or disabling bleeding, cardiogenic shock, and acute
kidney injury were signiﬁcantly lower in the TAVR
group compared with the surgical cohort, but
surgery appeared to be safer in terms of major
vascular complications and need for permanent
pacemaker. Both methods provided symptomatic
improvement, measured as a reduction in New York
Heart Association functional class, although TAVR
patients had more dyspnea after 1 year, possibly
related to a higher risk of paravalvular regurgita-
tion. This provocative study suggests that TAVR is
an alternative to SAVR in the treatment of severe
symptomatic elderly AS patients whose surgical risk
is low.
However, several limitations make the ﬁndings less
than conclusive. During a period of approximately
3.5 years, 1,576 patients in 3 hospitals were evaluatedby heart teams, but only 280 patients were included
in the study (mean age: 79 years). It is difﬁcult to
describe a study that enrolled <20% of screened pa-
tients as an all-comers trial. Also, the NOTION study
was designed to test TAVR’s superiority with sample
size calculated on the assumption that primary
outcome would occur 3 times more frequently in the
SAVR cohort. Given the similar outcomes, it turns out
that NOTION is an underpowered study that provides
valuable but not deﬁnitive data.
An important difference between the 2 groups was
the rate of post-TAVR aortic regurgitation (AR),
which was 4 times more frequent after TAVR than
SAVR. It is difﬁcult to envision widespread applica-
tion of TAVR in low-risk patients unless the para-
valvular AR issue is addressed effectively. Data from
the PARTNER trials and a recent meta-analysis indi-
cate an association between mild AR and increased
1- to 2-year mortality (8,9). Advances in imaging have
led to more precise measurement of the aortic
annulus and placement of appropriately-sized pros-
thesis. In the NOTION trial, 3-dimensional imaging of
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2197the annulus was not performed, perhaps resulting in
higher post-procedural AR.
New-generation transcatheter valves promise to
eliminate moderate and severe AR and reduce mild
AR cases. Recently, data from the PARTNER Sapien
3 registry provided the ﬁrst large-scale assess-
ment of lower-risk patient outcomes. At the 2015
American College of Cardiology Scientiﬁc Sessions,
Kodali et al. (8) presented 30-day outcomes for 1,076
intermediate-risk (STS score 4 to 8) patients treated
with the Sapien 3 valve (Edwards Lifesciences, Irvine,
California) (89% transfemoral). In this cohort, with an
average age of 81.9 years and average STS score of
5.3%, the 30-day rates of all-cause mortality and
disabling stroke were 1.1% and 1.0%, respectively.
Importantly, AR rates were much lower than previ-
ously reported, with moderate and severe AR seen in
3.4% of patients. This concurs with ﬁndings of small
studies evaluating valves with innovative designs
that also indicate that very low AR rates are possible.
In the NOTION trial, 38% of patients required
pacemaker implantation within 1 year of TAVR
compared with only 2.4% of SAVR patients, a 16-fold
difference. It would be difﬁcult to advise a low-risk,
AS patient to have TAVR with these odds.
What should practitioners do in light of the
NOTION study? The data are not robust enough to
support performing TAVR in all patients age $70years and candidates for ﬁrst-time open heart
surgery for isolated aortic valve replacement. We
should await the results of the randomized trials of
intermediate-risk patients and continue to carefully
evaluate outcomes in lower-risk patients, including
those treated with new-generation valves. In addi-
tion to the registry studies and randomized clinical
trials, heart teams should track their own institu-
tional outcomes, local resources, and capabilities
while answering the question “What is the best
treatment for our patient?”
Rather than performing another industry-
sponsored, expensive randomized trial, the recently
established STS/American College of Cardiology/TVT
registry can be used to further our understanding of
TAVR’s role in treating low-risk AS patients. Detailed
data are prospectively collected from all but a small
number of TAVR procedures performed in the United
States. Similarly, STS collects detailed SAVR data
from most U.S. centers. These 2 registries can serve as
a platform to organize studies to compare the effec-
tiveness of TAVR and SAVR in patient populations
that have not yet been studied.
REPRINT REQUESTS AND CORRESPONDENCE: Dr. E.
Murat Tuzcu, Department of Cardiology, Heart and
Vascular Institute, Cleveland Clinic, 9500 Euclid Avenue,
J2-3, Cleveland, Ohio, 44195. E-mail: tuzcue@ccf.org.RE F E RENCE S1. Leon MB, Smith CR, Mack M, et al. Trans-
catheter aortic-valve implantation for aortic ste-
nosis in patients who cannot undergo surgery.
N Engl J Med 2010;363:1597–607.
2. Kapadia SR, Leon MB, Makkar RR, et al. 5-year
outcomes of transcatheter aortic valve replace-
ment compared with standard treatment for pa-
tients with inoperable aortic stenosis (PARTNER 1):
a randomised controlled trial. Lancet 2015 Mar 15
[E-pub ahead of print].
3. Smith CR, Leon MB, Mack MJ, et al. Trans-
catheter versus surgical aortic-valve replacement
in high-risk patients. N Engl J Med 2011;364:
2187–98.
4. Adams DH, Popma JJ, Reardon MJ, et al.
Transcatheter aortic-valve replacement with aself-expanding prosthesis. N Engl J Med 2014;
370:1790–8.
5. Holmes DR Jr., Brennan JM, Rumsfeld JS, et al.
Clinical outcomes at 1 year following transcatheter
aortic valve replacement. JAMA 2015;313:1019–28.
6. Piazza N, Kalesan B, van Mieghem N, et al.
A 3-center comparison of 1-year mortality out-
comes between transcatheter aortic valve im-
plantation and surgical aortic valve replacement
on the basis of propensity score matching among
intermediate-risk surgical patients. J Am Coll
Cardiol Intv 2013;6:443–51.
7. Thyregod HGH, Steinbrüchel DA, Ihlemann N,
et al. Transcatheter versus surgical aortic valve
replacement in patients with severe aortic
valve stenosis: 1-year results from the all-comersNOTION randomized clinical trial. J Am Coll Car-
diol 2015;65:2184–94.
8. Kodali S, Pibarot P, Douglas PS, et al. Para-
valvular regurgitation after transcatheter aortic
valve replacement with the Edwards sapien valve
in the PARTNER trial: characterizing patients and
impact on outcomes. Eur Heart J 2015;36:449–56.
9. Athappan G, Patvardhan E, Tuzcu EM, et al.
Incidence, predictors, and outcomes of aortic
regurgitation after transcatheter aortic valve
replacement: meta-analysis and systematic review
of literature. J Am Coll Cardiol 2013;61:1585–95.KEY WORDS aortic stenosis, surgical AVR,
TAVR
